MX2019002728A - Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres. - Google Patents

Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres.

Info

Publication number
MX2019002728A
MX2019002728A MX2019002728A MX2019002728A MX2019002728A MX 2019002728 A MX2019002728 A MX 2019002728A MX 2019002728 A MX2019002728 A MX 2019002728A MX 2019002728 A MX2019002728 A MX 2019002728A MX 2019002728 A MX2019002728 A MX 2019002728A
Authority
MX
Mexico
Prior art keywords
antibody
kinase
combination
hematological cancers
delta inhibitor
Prior art date
Application number
MX2019002728A
Other languages
English (en)
Spanish (es)
Inventor
Sportelli Peter
s weiss Michael
P Miskin Hari
Original Assignee
Tg Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tg Therapeutics Inc filed Critical Tg Therapeutics Inc
Publication of MX2019002728A publication Critical patent/MX2019002728A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MX2019002728A 2016-09-09 2017-09-08 Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres. MX2019002728A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662385723P 2016-09-09 2016-09-09
PCT/US2017/050825 WO2018049263A1 (en) 2016-09-09 2017-09-08 Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers

Publications (1)

Publication Number Publication Date
MX2019002728A true MX2019002728A (es) 2019-08-16

Family

ID=59969229

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002728A MX2019002728A (es) 2016-09-09 2017-09-08 Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres.

Country Status (13)

Country Link
US (1) US20190247399A1 (enExample)
EP (1) EP3509634A1 (enExample)
JP (1) JP2019526595A (enExample)
KR (1) KR20190068521A (enExample)
CN (1) CN110191720A (enExample)
AU (1) AU2017322501A1 (enExample)
BR (1) BR112019004185A2 (enExample)
CA (1) CA3035976A1 (enExample)
CL (1) CL2019000585A1 (enExample)
EA (1) EA201990374A1 (enExample)
IL (1) IL265194A (enExample)
MX (1) MX2019002728A (enExample)
WO (1) WO2018049263A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3478723T3 (fi) 2016-06-29 2026-03-17 Checkpoint Therapeutics Inc Pd-l1-spesifisiä vasta-aineita ja niiden käyttömenetelmiä
PT3448859T (pt) 2017-03-20 2019-10-25 Forma Therapeutics Inc Composições de pirrolopirrole como ativadores de piruvato quinase (pkr).
CN108743947B (zh) * 2018-07-04 2020-12-15 复旦大学附属肿瘤医院 一种治疗b细胞淋巴瘤的药物组合物
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
WO2020191022A1 (en) * 2019-03-18 2020-09-24 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 9x
WO2021009509A1 (en) * 2019-07-15 2021-01-21 Johnson Matthey Public Limited Company Amorphous umbralisib monotosylate
CN114615977B (zh) 2019-09-19 2025-01-14 诺沃挪第克健康护理股份公司 丙酮酸激酶r(pkr)活化组合物
CN117222413A (zh) * 2021-02-10 2023-12-12 同润生物医药(上海)有限公司 治疗肿瘤的方法和组合
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
KR20240155263A (ko) * 2022-02-28 2024-10-28 재스퍼 테라퓨틱스 인코포레이티드 병든 조혈 줄기 세포를 고갈시키기 위한 조성물 및 방법
CN115141092A (zh) * 2022-07-27 2022-10-04 诚达药业股份有限公司 一种抗淋巴瘤药物相关化合物的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6190370B1 (en) 1997-07-25 2001-02-20 Arrow International, Inc. Devices, systems and methods for determining proper placement of epidural catheters
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
FR2844455B1 (fr) 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
FR2879204B1 (fr) 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
WO2009055343A2 (en) * 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP2328920A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
PT2496567T (pt) 2009-11-05 2017-11-15 Rhizen Pharmaceuticals S A Novos moduladores de quinase benzopiran
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
JP6240600B2 (ja) 2011-07-24 2017-11-29 キュアテク リミテッド ヒト化免疫モノクローナル抗体の変異体
EP3939613A1 (en) * 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
KR101988079B1 (ko) 2012-07-04 2019-06-11 리젠 파마슈티컬스 소시에떼 아노님 선택적 pi3k 델타 억제제
CA2886433C (en) 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
US9694071B2 (en) * 2012-11-02 2017-07-04 Tg Therapeutics, Inc. Combination of anti-CD20 antibody and PI3 kinase selective inhibitor
CA2949932C (en) 2014-05-27 2021-08-10 Rhizen Pharmaceuticals Sa Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations
SI3179992T1 (sl) * 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
EP3191126B1 (en) * 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors

Also Published As

Publication number Publication date
IL265194A (en) 2019-05-30
CN110191720A (zh) 2019-08-30
EP3509634A1 (en) 2019-07-17
AU2017322501A1 (en) 2019-03-28
CA3035976A1 (en) 2018-03-15
CL2019000585A1 (es) 2020-05-29
WO2018049263A1 (en) 2018-03-15
US20190247399A1 (en) 2019-08-15
EA201990374A1 (ru) 2019-09-30
JP2019526595A (ja) 2019-09-19
BR112019004185A2 (pt) 2019-09-03
KR20190068521A (ko) 2019-06-18

Similar Documents

Publication Publication Date Title
MX2019002728A (es) Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
BR112019005823A2 (pt) tratamento para enxaqueca refratária
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
ZA202005388B (en) Methods of treating ulcerative colitis
TR201812261T4 (tr) Pi3 ki̇naz i̇zoform modülatörleri̇ i̇le kanser tedavi̇si̇
EA201892294A1 (ru) Антитела и композиции против tim-3
MX375325B (es) Combinacion de anticuerpo anti-cd20 e inhibidor selectivo de pi3 cinasa.
EP3964527A3 (en) Combination therapy for cancer
MX2025001102A (es) Uso de virus oncoliticos, solos o en combinacion con un inhibidor de punto de control, para el tratamiento del cancer
HK1210786A1 (en) Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
MX2018003713A (es) Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
MX2017006464A (es) Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton.
MX370573B (es) Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
MY204336A (en) Compositions and methods for treating anemia
MX2020008569A (es) Inhibidores selectivos de bcl-2 en combinacion con un anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento de tipos de cancer.
MX2017016353A (es) Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos.
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
MX2018001369A (es) Combinaciones de inhibidores de tirosina quinasa de bruton y sus usos.
WO2019168897A3 (en) Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
PH12017501881A1 (en) Methods for treating cancer